<?xml version="1.0" encoding="UTF-8"?>
<p>Approximately 20% of all chronically infected individuals reside in the Middle East and North Africa (MENA)
 <xref rid="hep41491-bib-0003" ref-type="ref">3</xref>, 
 <xref rid="hep41491-bib-0004" ref-type="ref">4</xref>, 
 <xref rid="hep41491-bib-0005" ref-type="ref">5</xref> and mostly in the two countries most affected by HCV infection, Egypt
 <xref rid="hep41491-bib-0008" ref-type="ref">8</xref>, 
 <xref rid="hep41491-bib-0009" ref-type="ref">9</xref> and Pakistan.
 <xref rid="hep41491-bib-0010" ref-type="ref">10</xref>, 
 <xref rid="hep41491-bib-0011" ref-type="ref">11</xref> Direct‚Äêacting antivirals (DAAs), a highly effective treatment that was recently developed, has provided the opportunity to control HCV transmission and its disease burden.
 <xref rid="hep41491-bib-0012" ref-type="ref">12</xref> Therefore, the World Health Organization (WHO) has set a goal to eliminate HCV globally by 2030.
 <xref rid="hep41491-bib-0005" ref-type="ref">5</xref>, 
 <xref rid="hep41491-bib-0013" ref-type="ref">13</xref>, 
 <xref rid="hep41491-bib-0014" ref-type="ref">14</xref>
</p>
